Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer
- DOI
- 10.1021/acs.jmedchem.5c01184
- Published
- 2025-09-05
- Container
- Journal of Medicinal Chemistry
- Publisher
- American Chemical Society (ACS)
- Open access
- unknown
Credibility signals
uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.
Show all credibility signals
- supportingDOI registered: A matching record was returned by Crossref.
- supportingDOI resolves: A matching record was returned by Crossref.
- not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility.
- not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made.
- not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made.
- not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made.
- not scoredROR affiliation: Not checked or no result supplied; no credibility inference made.
- not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete.
- not scoredOpen access status: Not checked or no result supplied; no credibility inference made.
- not scoredPublication license: Not checked or no result supplied; no credibility inference made.
- not scoredPublication version: A publication version was supplied but is not scored.
- supportingMetadata completeness: All 6 scored descriptive metadata groups are present.
Cite this work
BibTeX
@article{allodium:10.1021/acs.jmedchem.5c01184,
title = {Development of
Optimized Exatecan-Based Immunoconjugates
with Potent Antitumor Efficacy in HER2-Positive Breast Cancer},
author = {Etienne Auvert and Emmanuel Douez and Louis Jolivet and Tiffany Witkowski and Anne-Catherine Jallas and Fanny Boursin and Ioana Molnar and Cyril Colas and Sandrine Valsesia Wittmann and Manon Auriol and Jean-Michel Chezal and Nicolas Aubrey and Emilie Allard-Vannier and Aurélie Maisonial-Besset and Nicolas Joubert and Caroline Denevault-Sabourin},
year = {2025},
journal = {Journal of Medicinal Chemistry},
doi = {10.1021/acs.jmedchem.5c01184},
url = {https://doi.org/10.1021/acs.jmedchem.5c01184}
}RIS
TY - JOUR TI - Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer AU - Etienne Auvert AU - Emmanuel Douez AU - Louis Jolivet AU - Tiffany Witkowski AU - Anne-Catherine Jallas AU - Fanny Boursin AU - Ioana Molnar AU - Cyril Colas AU - Sandrine Valsesia Wittmann AU - Manon Auriol AU - Jean-Michel Chezal AU - Nicolas Aubrey AU - Emilie Allard-Vannier AU - Aurélie Maisonial-Besset AU - Nicolas Joubert AU - Caroline Denevault-Sabourin PY - 2025 JO - Journal of Medicinal Chemistry DO - 10.1021/acs.jmedchem.5c01184 UR - https://doi.org/10.1021/acs.jmedchem.5c01184 ER -
APA
Auvert, E., Douez, E., Jolivet, L., Witkowski, T., Jallas, A., Boursin, F., Molnar, I., Colas, C., Wittmann, S. V., Auriol, M., Chezal, J., Aubrey, N., Allard-Vannier, E., Maisonial-Besset, A., Joubert, N., & Denevault-Sabourin, C. (2025). Development of Optimized Exatecan-Based Immunoconjugates with Potent Antitumor Efficacy in HER2-Positive Breast Cancer. Journal of Medicinal Chemistry. https://doi.org/10.1021/acs.jmedchem.5c01184
Source records
- crossref · retrieved 2026-09-27T06:24:44.917Z